SCHEMBL21471576

SCHEMBL21471576

O=c1ccccc(-c2ccccc2)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 6/20 1.00
HDAC2 Q92769 6/20 1.00
HDAC8 Q9BY41 6/20 1.00
HDAC6 Q9UBN7 1/20 1.00
HNF4A P41235 1/20 0.55
DBH P09172 3/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
BCL2L1 Q07817 1/20 0.52
HSD17B10 Q99714 1/20 0.52
BACE1 P56817 2/20 0.48
MMP2 P08253 1/20 0.48
P2RX7 Q99572 1/20 0.45
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
BCAT2 O15382 1/20 0.43
MEN1 O00255 1/20 0.43
MAOA P21397 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10481639 0.87 HDAC4 (0.77) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL21471577 0.83 HDAC4 (0.70) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL60283 0.79 HDAC4 (0.65) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL30605196 0.79 HDAC4 (0.65) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL7616374 0.79 HDAC4 (0.65) HDAC4HDAC2HDAC8HDAC6DBH
SCHEMBL10481650 0.78 HDAC4 (1.00) HDAC4HDAC2HDAC8HDAC6ALDH1A1
SCHEMBL5389905 0.77 HDAC4 (0.62) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL15437890 0.77 HDAC4 (0.62) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL9487300 0.77 HDAC4 (0.62) HDAC4HDAC2HDAC8HDAC6HNF4A
SCHEMBL275842 0.77 HDAC4 (0.62) HDAC4HDAC2HDAC8HDAC6HNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073131-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) 2024-04-04 WO disclosed
US-20210163393-A1 HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2021-06-03 US disclosed
WO-2019200314-A2 HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163393-A1 HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF CYP27A1, CYP27B1, HSD17B7 HDAC4 1472/4885HDAC2 766/4885HDAC8 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.